Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies

Area of Science:

• Oncology
• Medical Science

Background:

• Metastatic prostate cancer treatment remains a significant clinical challenge.
• Emerging targeted therapies offer new hope for patients with advanced disease.

Purpose of the Study:

• To review current clinical trials targeting tumor-associated cell surface antigens in metastatic prostate cancer.
• To discuss novel therapeutic strategies, including radioligand therapy, bispecific T cell engagers, antibody-drug conjugates, and CAR T cell therapies.
• To explore sequential and combinational treatment approaches.

Main Methods:

• Review of ongoing and completed clinical trials.
• Identification of key therapeutic targets such as prostate-specific membrane antigen (PSMA), STEAP1, KLK2, PSCA, and DLL3.
• Analysis of therapeutic strategies and their potential combinations.

Main Results:

• Several tumor-associated cell surface antigens are being actively targeted in clinical trials.
• Promising therapeutic agents include radioligand therapies, bispecific T cell engagers, antibody-drug conjugates, and CAR T cell therapies.
• Sequential and combination therapy strategies are under investigation to enhance treatment efficacy.

Conclusions:

• Targeting cell surface antigens represents a promising frontier in metastatic prostate cancer treatment.
• The development of novel agents and strategic combinations holds potential for improved patient outcomes.
• Further clinical investigation is warranted to optimize these innovative therapeutic approaches.